Cancer Biomarkers Market Growth Analysis, Segmentation, Size, Share, Trend by Forecast to 2026

Author : NitaSonwane
Publish Date : 2020-10-15 12:31:20


Cancer Biomarkers Market Growth Analysis, Segmentation, Size, Share, Trend by Forecast to 2026

The global cancer biomarkers market size is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers. As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.

List of Key Cancer Biomarker Market Manufacturers:

  • Myriad RBM
  • Abbott
  • Hoffmann-La Roche Ltd.
  • BioVision Inc.
  • Thermo Fisher Scientific
  • R&D System
  • Bio-Rad Laboratories, Inc.
  • Sino Biological Inc.
  • CENTOGENE N.V.
  • Sino Biological Inc.
  • Axon Medchem

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630

Report Highlights

The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website.

Market Drivers

Rise in Prevalence of Cancer Worldwide to Augment Growth

The increasing prevalence of cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue in the coming years.

Significant Industry Developments of Cancer Biomarkers Market Include:

March 2018 – Oncotype DX AR-V7 nucleus detect test, a predictive and prognostics biomarker was launched by Genomic Health Inc. The test helps in therapeutic decisions among patients who suffer from metastatic castration-resistant prostate cancer (mCRPC) by recognizing a connected variant of the androgen receptor protein namely AR-V7 situated in the nucleus of the circulating tumor cells (CTCs).

November 2018 – A collaborative agreement was signed between AstraZeneca and Biocartis Group NV to obtain molecular diagnostics biomarker for quick results in lung cancer patients across the European region.

Competitive Landscape:

Substantial Investment in Research and Development of Novel Therapeutics to Escalate Market Competition

The global cancer biomarker market is semi-consolidated in nature. Notable players operating in the market are engaging in strategic collaborations such as mergers and acquisitions, joint ventures, company collaborations, and others to gain an edge in the market competition. Apart from this, players are investing massive amounts into research and development of novel therapeutic solutions for various cancer types. Thermo Fisher Scientific, Inc., Abbott, and F. Hoffmann-La Roche Ltd. are currently holding dominant cancer biomarker market shares.



Category : business

Palo Alto Networks PCNSA Dumps - Confirmed Success In Actual PCNSA Exam

Palo Alto Networks PCNSA Dumps - Confirmed Success In Actual PCNSA Exam

- Prepare yourself with the best and updated ACFE CFE-Fraud-Prevention-and-Deterrence dumps pdf created by QualityDumps and easily be triumphant in your CFE-Fraud


Six Nations: Should rugby tournament implement promotion and relegation? cannabises

Six Nations: Should rugby tournament implement promotion and relegation? cannabises

- Georgias head coach Milton Haig speaks to CNNs Alex Thomas about his teams hopes of taking part i


Best Software Architect Job Description Template

Best Software Architect Job Description Template

- Were looking for a highly-skilled Software Architect to direct our development staff in producing software solutions that satisfy our customers requirements.


What are the benefits of Latex Pillow?

What are the benefits of Latex Pillow?

- Pillows are considered a necessity for comfort and relaxation during sleep. Pillows are really useful and this is not only you need a pillow in bedrooms but also you may need them in the office while